ProQR Therapeutics NV (NAS:PRQR)
$ 1.88 -0.01 (-0.53%) Market Cap: 153.53 Mil Enterprise Value: 63.26 Mil PE Ratio: 0 PB Ratio: 4.06 GF Score: 39/100

ProQR Therapeutics NV Expert Perspectives Series -- Usher Syndrome and Retinitis Pigmentosa - Call Transcript

Jun 22, 2020 / 04:00PM GMT
Hans Vitzthum
LifeSci Advisors, LLC - MD

Good afternoon, and welcome to the ProQR Expert Perspectives Call on Usher Syndrome. (Operator Instructions) Today's call is being recorded, and a replay will be made available on the ProQR website at the conclusion of the event.

At this time, I'd like to turn the call over to your host, Dr. Aniz Girach, Chief Medical Officer at ProQR. Aniz, the floor is yours.

Aniz Girach
ProQR Therapeutics N.V. - Chief Medical Officer

Thanks, Hans, and a very warm welcome to everyone who's joining us today. My name is Aniz Girach. I'm the Chief Medical Officer for ProQR. I'm an ophthalmologist by training also. And my background is that I've spent the last 25 years working in the industry, working for big companies as well as smaller companies and biotech and start-ups as well as having the pleasure of -- and the honor of having worked on a number of ophthalmic approvals in the past. I've also had the opportunity to work on biologics as well as small molecules, and then more recently with my last job, with gene therapy as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot